G-Protein Coupled Receptors Market Report 2025

The G-protein coupled receptors market size has grown strongly in recent years. It will grow from $3.2 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to drug discovery advances, FDA approvals, genomic discoveries, emerging markets, market consolidation, growing aging population.

The G-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.46 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to personalized medicine, increased focus on rare diseases, artificial intelligence in drug discovery, patient-centric drug development, environmental and social factors, biosimilar market growth. Major trends in the forecast period include biotechnology advancements, increased r&d investment, technological innovations, collaborations and partnerships, digital therapeutics.

The increasing prevalence of cancer is expected to drive the growth of the G-protein-coupled receptors (GPCRs) market in the coming years. Cancer is a disease characterized by the uncontrolled spread of abnormal cells, which can invade surrounding tissues and disseminate through the body’s lymphatic and vascular systems. GPCRs play a crucial role in regulating processes that are key to cancer progression, such as proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and activation of invasion and metastasis. For example, in January 2023, the American Cancer Society, a US-based professional organization, reported that there were 1,958,310 new cancer cases diagnosed in the United States in 2023, an increase from the estimated 1.9 million new cases in 2022. Thus, the rising prevalence of cancer is significantly driving the growth of the G-protein-coupled receptors market.

Rising healthcare expenditures are expected to drive the growth of the G-protein-coupled receptors (GPCRs) market. Healthcare expenditures encompass the total spending on healthcare-related services, products, and activities over a specific period, whether at the individual, community, national, or global level. Increased healthcare spending typically results in the expansion of healthcare services and facilities, which, in turn, leads to a higher demand for GPCR-targeted drugs as healthcare providers seek advanced and innovative treatments for various diseases and conditions. For instance, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that UK healthcare expenditure reached approximately $354.88 billion (£283 billion), marking a nominal increase of 0.7% compared to 2021. Therefore, the rise in healthcare expenditures is expected to significantly contribute to the growth of the G-protein-coupled receptors market.

A prominent trend gaining traction in the G-protein-coupled receptor (GPCR) market is the strategic investment to advance GPCR screening and antibody development. Leading companies in the GPCR sector are actively seeking investments to propel the development of drugs and medication technologies associated with GPCR-related diseases. For example, in February 2023, LifeArc Ventures, a venture capital firm based in the UK, invested $16 million in Maxion Therapeutics, a UK-based drug discovery company. This investment aims to advance antibody development for previously untreatable ion channel and GPCR-driven disorders, leveraging the proprietary KnotBody technology for the development of antibody therapeutics targeting ion channels and GPCRs.

Major companies in the G-protein-coupled receptors (GPCRs) market are initiating Initial Public Offerings (IPOs) to enhance their development of drugs targeting GPCRs. This move aims to accelerate research and development, advance clinical trials, and introduce innovative therapies for various diseases, including cancer, neurological disorders, and metabolic conditions. The funds raised from these IPOs will primarily support the development of the companies' lead product candidates aimed at chronic metabolic and pulmonary diseases. In particular, the proceeds are designated for advancing their glucagon-like peptide-1 receptor (GLP-1R) agonist program, which focuses on diabetes and obesity treatments. For example, in February 2023, Structure Therapeutics Inc., a US-based company, successfully completed its IPO, raising $161 million to further its development of GPCR-based therapeutics. The company offered 10,740,000 American depositary shares (ADSs) at $15.0 per ADS, significantly exceeding its initial projections. The shares began trading on the Nasdaq Global Market under the ticker symbol "GPCR."

In December 2023, Danaher Corporation, a US-based company, acquired Abcam Plc for an undisclosed amount. This acquisition is intended to enhance Danaher’s portfolio by integrating Abcam's expertise in G-protein-coupled receptors (GPCRs). Abcam Plc is a UK-based company that specializes in the provision of GPCRs.

Major companies operating in the G-protein coupled receptors market include Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Danaher Corporation, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Thermo Fisher Scientific Inc., Perkin Elmer Inc., Qiagen N.V., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Escient Pharmaceuticals Inc., Structure Therapeutics, Septerna.

North America was the largest region in the G-protein coupled receptors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g-protein coupled receptors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-protein coupled receptors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

G-protein coupled receptors, also known as seven-(pass)-transmembrane receptors, are a type of membrane receptor located in the cell membrane. Their primary function is to bind extracellular chemicals and transmit signals from these substances to intracellular molecules. Representing the largest family of membrane proteins, GPCRs play a pivotal role in mediating cellular responses to hormones and neurotransmitters. They are responsible for functions such as vision, olfaction, and taste.

The main offerings associated with G-protein-coupled receptors include cell lines, detection kits, cell culture reagents, and ligands. A cell line refers to a selected uniform cell culture derived from a population of cells typically sourced from a homogeneous tissue. Various types of assays, including camp functional assays, calcium functional assays, β-arrestin functional assays, radioligand binding and GTPγS functional assays, internalization assays, and trafficking assays, are employed in diverse applications. These applications span areas such as cancer research, CNS research, metabolic research, cardiovascular research, inflammation research, respiratory research, and others.

The G-protein-coupled receptors market research report is one of a series of new reports that provides G-protein-coupled receptors market statistics, including the G-protein-coupled receptors industry global market size, regional shares, competitors with a G-protein-coupled receptors market share, detailed G-protein-coupled receptors market segments, G-protein-coupled receptors market trends, and opportunities, and any further data you may need to thrive in the G-protein-coupled receptors industry. This G-protein-coupled receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The G-protein-coupled receptors market consists of revenues earned by entities by providing GPCR screening and profiling services, GPCR antibodies and immunoassays, hormones visual control. The market value includes the value of related goods sold by the service provider or included within the service offering. The G-protein-coupled receptors market also includes sales of adenosine, serotonin, and metabotropic receptor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.